ZURICH, Sept 21 European regulators on Friday
issued positive opinions for new indications of Novartis AG
drugs Galvus and Eucreas in combination with other
treatments for type 2 diabetes patients.
The Committee for Medicinal Products for Human Use (CHMP)
issued a positive opinion for Galvus in combination with
insulin, with or without metformin, for patients with type 2
diabetes when diet, exercise and a stable dose of insulin do not
result in glycemic control.
The second positive opinion was for Eucreas in triple
combination with metformin and sulphonylurea also for the
treatment of type 2 diabetes when diet and exercise plus dual
therapy with these two agents do not provide adequate glycemic
Galvus is already approved in more than 100 countries and
Eucreas in over 80 countries.
(Reporting by Andrew Thomspson)